Oncternal Therapeutics, Inc. — Net Income by Fiscal Year

15 fiscal years, as filed with the SEC; every row links its evidence fact.

Cite as: FACTANKER, https://factanker.com/entity/66757c5f-bb46-4760-86e2-e06130daaf6f/serie/net-income

Fiscal year	Net Income	Period	Evidence
FY 2023	$-39.5M	2023-01-01 – 2023-12-31	evidence 0000950170-24-027984
FY 2022	$-44.2M	2022-01-01 – 2022-12-31	evidence 0000950170-23-007062
FY 2021	$-31.3M	2021-01-01 – 2021-12-31	evidence 0001564590-22-009702
FY 2020	$-17.2M	2020-01-01 – 2020-12-31	evidence 0001564590-21-012588
FY 2019	$-34.2M	2019-01-01 – 2019-12-31	evidence 0001564590-20-011213
FY 2018	$-6.6M	2018-01-01 – 2018-12-31	evidence 0001564590-20-011213
FY 2017	$-30.4M	2017-01-01 – 2017-12-31	evidence 0001047469-18-001564
FY 2016	$-17.7M	2016-01-01 – 2016-12-31	evidence 0001047469-17-001982
FY 2015	$-18.7M	2015-01-01 – 2015-12-31	evidence 0001047469-16-011178
FY 2014	$-39.4M	2014-01-01 – 2014-12-31	evidence 0001047469-15-002283
FY 2013	$-42.1M	2013-01-01 – 2013-12-31	evidence 0001104659-14-018791
FY 2012	$-27.1M	2012-01-01 – 2012-12-31	evidence 0001047469-13-002200
FY 2011	$-33.3M	2011-01-01 – 2011-12-31	evidence 0001193125-12-093770
FY 2010	$15.3M	2010-01-01 – 2010-12-31	evidence 0001193125-12-093770
FY 2009	$-46.3M	2009-01-01 – 2009-12-31	evidence 0001193125-12-093770

Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).

Oncternal Therapeutics, Inc. — all facts · Revenue · Operating Income